12:52 PM
 | 
Jul 28, 2017
 |  BC Week In Review  |  Company News  |  Deals

Amgen gets rights to Captisol formulation technology for BiTE AMG 330

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Amgen Inc. (NASDAQ:AMGN) exclusive, worldwide commercialization rights to combine Captisol formulation technology with AMG 330 to treat...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >